Overview
The words get used interchangeably, including by clinicians, and the distinction matters more than almost any other terminology question in hormone therapy.
Progesterone is the hormone the human body produces. Progestins are a family of synthetic compounds designed to act on the progesterone receptor. They are not one thing — different progestins have quite different additional activities, because they were designed from different parent molecules.
"Progestogen" is the umbrella term covering both, and it is the correct word when you mean the whole category.
| Progesterone (micronized) | Progestins (synthetic) | |
|---|---|---|
| Structure | Identical to what the body produces | Related but structurally different |
| Consistency as a group | One molecule | Many different compounds, different properties |
| Endometrial protection | Established | Established, and generally strong |
| Effect on lipids | Broadly neutral | Varies by agent; some are unfavorable |
| Breast tissue effect | Observational data suggests a more favorable signal | Varies; the agent studied in WHI is the one with the clearest signal |
| Sedation | Yes, often welcome at night | Generally not |
| Other activities | Minimal | Some have androgenic, glucocorticoid or antimineralocorticoid activity |
Why this is worth a whole page: most of what the public believes about hormone therapy and breast cancer comes from one large trial that used a specific estrogen with a specific progestin. Neither is what is most commonly prescribed today. That does not make the trial wrong — it makes it narrower than it is usually presented.
Why progestins exist at all
Progesterone taken by mouth in its raw form is broken down too rapidly to work. For most of the twentieth century that made an oral progesterone product impractical.
Synthetic progestins were developed to solve it — molecules that resist breakdown, are active orally, and bind the progesterone receptor. They worked, and they made oral hormone therapy and hormonal contraception possible.
The complication is that these molecules are not simply progesterone-that-survives-digestion. Depending on which parent compound they were derived from, they carry additional activity: some are mildly androgenic, some have glucocorticoid activity, some are antimineralocorticoid. Those extra activities produce the differences in the table.
Micronized progesterone — progesterone ground into very fine particles and suspended in oil — solved the absorption problem differently, and became available much later. It is structurally identical to the body's own hormone and carries the additional activities of none of the synthetics.
What the WHI actually tested
This is where the distinction earns its importance.
The Women's Health Initiative is the trial behind the public understanding of hormone therapy risk, and its combined estrogen-plus-progestin arm reported an increased breast cancer signal that reshaped prescribing for a generation.
That arm used conjugated equine estrogens with medroxyprogesterone acetate — a specific estrogen and a specific progestin. Two things about it are consistently under-reported.
The estrogen-alone arm — in women who had had a hysterectomy, so no progestin — did not show the same increase. In that arm the breast cancer finding was not an increase.
And the participants were older than the women typically starting hormone therapy today, with an average age well above the usual age at menopause. Timing relative to menopause turns out to matter substantially for the risk-benefit balance.
None of this makes the trial's findings invalid. It makes them findings about that combination, in that population — which is not the same as findings about hormone therapy generally, and is certainly not findings about transdermal estradiol with micronized progesterone in a woman in her early fifties.
What the later evidence suggests
Large observational studies, particularly from France, have compared regimens using micronized progesterone with those using synthetic progestins.
The pattern that emerges is a more favorable breast signal for micronized progesterone, at least over the first several years of use, than for the synthetic progestins studied.
Two honest qualifications. This is observational data, not randomized, so residual confounding cannot be excluded — the women choosing different regimens may differ in ways that were not measured. And a more favorable signal is not the same as no risk; the evidence does not support telling anyone that micronized progesterone carries none.
What it does support is that the choice of progestogen is a real clinical variable rather than an interchangeable detail, and that lumping all of them together under "HRT causes breast cancer" is not what the evidence shows.
Where progestins remain the right choice
This is not an argument that progestins are bad, and it would be dishonest to present it that way.
They provide strong, well-established endometrial protection. Some have properties that are useful for specific problems — the antimineralocorticoid activity of one is helpful for fluid retention; the antiandrogenic activity of another is useful where acne or hirsutism is part of the picture.
A progestogen-releasing intrauterine system uses a progestin, delivers it locally to the endometrium, provides excellent protection and contraception simultaneously, and has minimal systemic exposure. For many women it is the best option available.
And some women simply do not tolerate micronized progesterone — the sedation, the dizziness, the mood effects — and do well on a progestin.
The point is not that one is right. It is that they are different, and the choice should be made deliberately.
Frequently asked questions
What is the difference between progestin and progesterone? Progesterone is the hormone the body produces. Progestins are synthetic compounds that act on the same receptor but differ structurally and carry additional activities that vary by agent. "Progestogen" covers both.
Is micronized progesterone safer than a progestin? Observational evidence suggests a more favorable breast cancer signal, particularly over the first several years. It is observational rather than randomized, and it does not mean no risk.
Does hormone therapy cause breast cancer? The picture is more specific than the headline. The increased signal in the WHI came from the combined arm using a particular estrogen and progestin; the estrogen-only arm did not show it. Risk varies by regimen, by duration and by when treatment starts relative to menopause.
Why is my prescription a progestin rather than progesterone? There are legitimate reasons — tolerability, a specific additional property that helps your picture, or an intrauterine system providing protection and contraception together. It is worth asking which applies to you.
Do I need a progestogen at all? If you have a uterus and take systemic estrogen, endometrial protection is required. Without a uterus, it generally is not.
Where this fits in your plan
The choice of progestogen is one of the more consequential decisions in a hormone therapy regimen, and it is frequently made by default rather than by discussion.
It is worth asking which one you are on, why that one, and whether an alternative fits your picture better — particularly if you are tolerating it poorly. What hormone therapy with us involves, and what it costs.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
